Abstract: The present invention relates to compounds of the general formula (I) which bind to and/or neutralise C-reactive protein. The compounds according to the invention are particularly useful for the treatment and/or prevention of acute or chronic diseases associated with and/or caused by elevated CRP levels.

Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.

Abstract: Chiral selectors having ?-unsubstituted ?-amino acid derivatives of the structure: a stationary phase for separating substance mixtures containing the chiral selector, and processes for separating mixtures of chiral substances, including enantiomers, and especially enantiomers of substances selected from ?-amino acids and derivatives thereof, ?-amino acids and ?-hydroxy acids are provided.

Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.

Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.

Abstract: Chiral selectors having ?-unsubstituted ?-amino acid derivatives of the structure: a stationary phase for separating substance mixtures containing the chiral selector, and processes for separating mixtures of chiral substances, including enantiomers, and especially enantiomers of substances selected from ?-amino acids and derivatives thereof, ?-amino acids and ?-hydroxy acids are provided.

Abstract: The invention relates to a method for determining the isoform composition of erythropoietin, comprising the following steps: a) isoelectrical focusing of a sample comprising erythropoietin in a gel over a pH range having a lower limit of 2.5 to 3.5 and an upper limit of 5 to 8, wherein the sample comprising erythropoietin originates from a culture supernatant of erythropoietin producing eukaryotic cells; b) transferring of the proteins comprised and separated in the gel to a membrane; c) verifying the erythropoietin bound to the membrane by specific antibodies; and to a method for in-process control of culture supernatants of erythropoietin producing eukaryotic cells during the fermentative production process.

Abstract: Chiral selectors having ?-unsubstituted ?-amino acid derivatives of the structure: a stationary phase for separating substance mixtures containing the chiral selector, and processes for separating mixtures of chiral substances, including enantiomers, and especially enantiomers of substances selected from ?-amino acids and derivatives thereof, ?-amino acids and ?-hydroxy acids are provided.

Abstract: The present invention relates to pharmaceutical compositions comprising gamma secretase modulators as well as to the use of gamma secretase modulators for treating renal disorders, cancer, neurodegenerative disorders as well as related disorders.

Abstract: The present invention relates to a process for the fermentative continuous production of erythropoietin, where eukaryotic erythropoietin-producing cells are cultured in a perfusion reactor while retaining the cells, the glucose concentration in the culture supernatant being adjusted via the perfusion rate and the cell number via the cell retention rate and/or the outward transferal of defined amounts of cell-containing culture medium from the bioreactor within preset zones.

Abstract: The present invention relates to a method for preparing erythropoietin, wherein culture supernatant of erythropoietin-producing eukaryotic cells containing erythropoietin are subjected to the following steps: a) Removing the cell components; and b) treating the product from a) to the following chromatography steps in the sequence indicated i) reversed phase chromatography; ii) anion exchange chromatography; iii) hydroxyapatite chromatography.

Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.

Abstract: Chiral selectors having ?-unsubstituted ?-amino acid derivatives of the structure: a stationary phase for separating substance mixtures containing the chiral selector, and processes for separating mixtures of chiral substances, including enantiomers, and especially enantiomers of substances selected from ?-amino acids and derivatives thereof, ?-amino acids and ?-hydroxy acids are provided.

Abstract: The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma.

Abstract: Heat exchange device with a plate element (1) which has a shaped part (5) which extends over a heat exchange surface, is of at least partly flexible design and forms a partial boundary of a cavity (13), through which a heat transfer medium can flow and which is tightly closed off on the base side by a web (11) which forms on the heat exchange surface the contact surface for the heat transfer to a body (3), against which body the plate element (1) can be placed, wherein a flexible retaining plate (21) for pressing the plate element (1) against the body (3) rests on that top side of the shaped part (5) which is remote from the heat exchange surface on the base side, and wherein the flexibility of retaining plate (21) and the deformability of shaped part (5) and web (11) on the base side are selected in such a way that the plate element (1) can be adapted to the geometry of the body (3).

Abstract: The invention relates to a cooling device for a machine tool (10) for cooling a heated fluid, for example a cooling lubricants, comprising at least one refrigerating unit (48) for a fluid which is filtered by a filtering unit (40) and is received form at least one storage tank (38) by means of a pumping unit provided with at least one hydraulic pump (P2), separated clean (22) and waste (36) tanks, wherein the refrigerating unit (48) returns the circulating cooled fluid to the clean tank (22).

Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence: R1-X01-X02-X03-X04-X05-X06-X07-X08-X09-X10-X11-X12-X13-R2. These peptides have a high affinity for immunoglobulins. Applications of the peptides according to the invention are also described.

Abstract: Peptides which bind auto-antibodies being in a causally pathological relationship with dilatative cardiomyopathy are described. The peptides may be bound, for example, to a solid phase. Auto-antibodies can be removed by treating blood of patients suffering from DCM with the peptides according to the invention.

Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence:

Abstract: The present invention relates to a process for the one-stage resalting and purification of oligopeptides. Oligopeptides are often not formed directly as acetates when synthesised. Acetate salts of oligopeptides are however desirable as bulk-active material for medical and formulation reasons. Processes known from the prior art have hitherto involved two separate steps or pyridine-containing solvents. The resalting and purification can be combined in one step and the use of pyridine as solvent can be avoided, if the oligopeptide in the form of its chloride salt is purified with an acetate-containing solvent by liquid chromatography methods.